Page last updated: 2024-08-22

camptothecin and mln 8237

camptothecin has been researched along with mln 8237 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L	1
Arcaroli, JJ; Bagby, SM; Bradshaw-Pierce, EL; Capasso, A; Davis, SL; Diamond, JR; Eckhardt, SG; Ecsedy, JA; Hyatt, SL; Klauck, PJ; McPhillips, K; Messersmith, WA; Pitts, TM; Purkey, A; Selby, HM; Spreafico, A; Tan, AC; Tentler, JJ	1

Trials

1 trial(s) available for camptothecin and mln 8237

Article	Year
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-20, Volume: 34, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult	2016

Article

Year

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-20, Volume: 34, Issue:12

Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult

2016

Other Studies

1 other study(ies) available for camptothecin and mln 8237

Article	Year
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget, 2016, Aug-02, Volume: 7, Issue:31 Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Azepines; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2016

Article

Year

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Azepines; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2016